AR047550A1 - Tratamiento de la depresion y otros trastornos afectivos - Google Patents
Tratamiento de la depresion y otros trastornos afectivosInfo
- Publication number
- AR047550A1 AR047550A1 ARP040102200A ARP040102200A AR047550A1 AR 047550 A1 AR047550 A1 AR 047550A1 AR P040102200 A ARP040102200 A AR P040102200A AR P040102200 A ARP040102200 A AR P040102200A AR 047550 A1 AR047550 A1 AR 047550A1
- Authority
- AR
- Argentina
- Prior art keywords
- depression
- treatment
- affective disorders
- gaboxadol
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300956 | 2003-06-25 | ||
DKPA200400016 | 2004-01-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047550A1 true AR047550A1 (es) | 2006-01-25 |
Family
ID=58707228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040102200A AR047550A1 (es) | 2003-06-25 | 2004-06-23 | Tratamiento de la depresion y otros trastornos afectivos |
Country Status (10)
Country | Link |
---|---|
KR (1) | KR20060025192A (ru) |
AR (1) | AR047550A1 (ru) |
CA (2) | CA2692334A1 (ru) |
CL (2) | CL2004001607A1 (ru) |
EA (1) | EA200600101A1 (ru) |
IS (1) | IS8138A (ru) |
ME (2) | MEP1908A (ru) |
NO (1) | NO20060229L (ru) |
RS (1) | RS20050911A (ru) |
TW (1) | TW200509918A (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
IL298334A (en) | 2020-05-20 | 2023-01-01 | Certego Therapeutics Inc | A canceled gaboxadol ring and its use for the treatment of psychiatric disorders |
-
2004
- 2004-06-15 TW TW093117156A patent/TW200509918A/zh unknown
- 2004-06-23 AR ARP040102200A patent/AR047550A1/es not_active Application Discontinuation
- 2004-06-24 CL CL200401607A patent/CL2004001607A1/es unknown
- 2004-06-25 ME MEP-19/08A patent/MEP1908A/xx unknown
- 2004-06-25 KR KR1020057024823A patent/KR20060025192A/ko not_active Application Discontinuation
- 2004-06-25 ME MEP-2008-19A patent/ME00030B/me unknown
- 2004-06-25 CA CA2692334A patent/CA2692334A1/en not_active Abandoned
- 2004-06-25 RS YUP-2005/0911A patent/RS20050911A/sr unknown
- 2004-06-25 CA CA002529805A patent/CA2529805A1/en not_active Abandoned
- 2004-06-25 EA EA200600101A patent/EA200600101A1/ru unknown
-
2005
- 2005-11-21 IS IS8138A patent/IS8138A/is unknown
-
2006
- 2006-01-16 NO NO20060229A patent/NO20060229L/no not_active Application Discontinuation
-
2010
- 2010-02-25 CL CL2010000166A patent/CL2010000166A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW200509918A (en) | 2005-03-16 |
IS8138A (is) | 2005-11-21 |
CL2004001607A1 (es) | 2005-05-27 |
MEP1908A (xx) | 2010-02-10 |
KR20060025192A (ko) | 2006-03-20 |
CL2010000166A1 (es) | 2010-07-02 |
CA2692334A1 (en) | 2004-12-29 |
RS20050911A (en) | 2007-08-03 |
ME00030B (me) | 2010-06-10 |
CA2529805A1 (en) | 2004-12-29 |
EA200600101A1 (ru) | 2006-06-30 |
NO20060229L (no) | 2006-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048878A1 (es) | Composiciones topicas de metadona y metodos para usarlas | |
UY28933A1 (es) | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos | |
CL2007002635A1 (es) | Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion. | |
ECSP11010975A (es) | Método de uso de una cepa de bacillus subtilis para mejorar la salud de animales | |
AR109263A2 (es) | Composición que comprende moxidectina | |
CY1110046T1 (el) | Γαβοξαδολη για τη θεραπεια της καταθλιψης και αλλων συναισθηματικων διαταραχων | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
HN2006000971A (es) | Metodos para preparar composiciones o formas de dosificacion que comprenden un agonista grp119 que tiene el efecto de un secretagogo glp-1 | |
CL2018001420A1 (es) | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853) | |
CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
CL2008001268A1 (es) | Compuestos derivados de n-[6-amino-5-aril-piridin-2-il]-carboxamida; composicion farmaceutica que los comprende; composicion farmaceutica combinada que los comprende junto a otro agente farmacologico adicional; y uso de los mismos en el tratamiento del dolor. | |
ECSP109852A (es) | Uso de homo y copolímeros para la estabilización de formulaciones de principios activos | |
ES2570856T3 (es) | Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros | |
ECSP088763A (es) | Nuevas combinaciones terapéuticas para el tratamiento de la depresión | |
BRPI0508680A (pt) | composição de resfriamento natural, composição flavorizante, produto pronto-para-consumo, e, uso de uma composição | |
CL2020001349A1 (es) | Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574) | |
AR047553A1 (es) | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina | |
AR056749A1 (es) | Formulaciones de dosificacion oral de ibuprofeno organolepticamente aceptables metodos para su preparacion y uso | |
AR074302A1 (es) | Trans-clomifeno para el sindrome metabolico y la diabetes mellitus tipo 2.. metodo | |
CO6551744A2 (es) | Combinación de fármacos con teobromina y su uso en terapia | |
PA8571901A1 (es) | Nueva composicion farmaceutica | |
AR062784A1 (es) | Tratmiento de los vertigos con acetil -l- leucina | |
AR072425A1 (es) | Uso de nifurtimox para el tratamiento de giardiasis | |
CL2008001477A1 (es) | Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |